Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology Learning Network
Osimertinib plus datopotamab deruxtecan produced 20.5-month median duration of response at the 6 mg/kg dose in EGFR-mutated NSCLC after first-line osimertinib progression in the ORCHARD platform substudy.
Hematology/Oncology April 28th 2026
Medical News Today (MNT)
Higher Healthy Eating Index scores and elevated oral contraceptive use co-occurred with young-onset lung cancer in a 187-patient nonsmoker cohort presented at AACR.
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS